<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="antiviral effects and safety limits. Abstract Given the speed of" exact="viral infection" post="spread, repurposing of existing drugs has been given the"/>
 <result pre="effects and safety limits. Abstract Given the speed of viral" exact="infection" post="spread, repurposing of existing drugs has been given the"/>
 <result pre="and reach patients quickly enough to help in the current" exact="disease" post="outbreak. Here, we have reviewed available evidence and possible"/>
 <result pre="interfere with endosomal pathway and intracellular membrane trafficking crucial for" exact="viral infection." post="With the aim to identify other lysosomotropic drugs with"/>
 <result pre="hERG, human Ether-Ã -go-go-Related Gene, a potassium ion channel in" exact="heart" post="QSAR, quantitative structure activity relationship CCR5, C-C chemokine receptor"/>
 <result pre="heart QSAR, quantitative structure activity relationship CCR5, C-C chemokine receptor" exact="type 5" post="Keywords COVID-19 Antiviral drugs Drug repositioning Lysosomotropism Endosomal pathway"/>
 <result pre="available antiviral drugs were mainly designed to target a specific" exact="viral" post="or human protein crucial for infection with a specific"/>
 <result pre="to target a specific viral or human protein crucial for" exact="infection" post="with a specific type of virus [1]. Considering the"/>
 <result pre="a single protein, but rather for a general mechanism of" exact="viral infection." post="For instance, chloroquine and hydroxychloroquine have been reported to"/>
 <result pre="have been reported to affect endosomes, the critical point of" exact="viral" post="entry into the cell, resulting in antiviral effect [2]."/>
 <result pre="cell, resulting in antiviral effect [2]. Various steps in the" exact="viral infection" post="have been examined to understand the mechanism of (hydroxy)chloroquineâ€™s"/>
 <result pre="resulting in antiviral effect [2]. Various steps in the viral" exact="infection" post="have been examined to understand the mechanism of (hydroxy)chloroquineâ€™s"/>
 <result pre="more acidic environment, they become protonated and as such cannot" exact="diffuse" post="back through the membrane. Consequently, as the drug moves"/>
 <result pre="biological membranes [11]. The importance of intracellular membranes in coronavirus" exact="infection" post="is immense. Firstly, viruses enter the cell by formation"/>
 <result pre="that is heavily bound to cellular membranes, negatively affects the" exact="viral" post="life cycle, if not even the structure of its"/>
 <result pre="the overload of cationic drug in the ER membrane, that" exact="viral" post="lipid envelope is made of, leads to serious disturbances"/>
 <result pre="consequence of their binding to membranes [12] and reduction of" exact="vesicle" post="trafficking in the cell [15,17]. Therefore, we anticipate that,"/>
 <result pre="far; by inhibiting endocytosis, increasing endosomal pH, and slowing down" exact="total" post="intracellular membrane trafficking [22]. Their potency may be moderate"/>
 <result pre="the first line of defence in current and possible new" exact="viral" post="epidemic outbreaks. Another possible positive contribution of CADs in"/>
 <result pre="as well as well-known antimalarial drug chloroquine. In repurposing for" exact="viral" post="infections, additional types of toxicity may arise from their"/>
 <result pre="viral infections, additional types of toxicity may arise from their" exact="primary" post="pharmacological targets, as they were developed to treat completely"/>
 <result pre="ones could be found that may be reasonably safe during" exact="short" post="term treatment, at least for a group of COVID-19"/>
 <result pre="a group of COVID-19 patients that do not have pre-existing" exact="heart" post="and liver conditions. 2 Analysis of marketed existing drugs"/>
 <result pre="likelihood of interacting with cell compartments and processes critical for" exact="viral infection" post="cycle, such as endosomes, lysosomes and membranes in general."/>
 <result pre="of interacting with cell compartments and processes critical for viral" exact="infection" post="cycle, such as endosomes, lysosomes and membranes in general."/>
 <result pre="possible impact on membrane surface charge -Inhibition of lysosomal functions" exact="Primary" post="inclusion criterion Accumulation in cells ACC class (calc) 2âˆ’5(3âˆ’5b)"/>
 <result pre="high accumulation in endosomes/lysosomes -Slow-down of endocytosis -Increasing endosomal/lysosomal pH" exact="Primary" post="inclusion criterion Protonizability pKa (basic) (exp or calc) â‰¥"/>
 <result pre="charge in acidic environments (lysosomes and endosomes) -Increasing endosomal/lysosomal pH" exact="Primary" post="inclusion criterion Physiological charge (calc) â‰¥ 1 -Positive charge"/>
 <result pre="organism for a longer period [35]. Due to their strong" exact="primary" post="pharmacology we have excluded psychoactive compounds and antiarrhythmics from"/>
 <result pre="as we think that these compounds, with strong effects on" exact="brain" post="and hearth, are not suitable for repurposing for fighting"/>
 <result pre="brain and hearth, are not suitable for repurposing for fighting" exact="viral" post="infections. There is a strong possibility that they may"/>
 <result pre="given at higher doses than what is needed for their" exact="primary" post="indication. It would, however, be important to know whether"/>
 <result pre="primary indication. It would, however, be important to know whether" exact="chronic" post="use of antidepressants, or any other CADs, can in"/>
 <result pre="CADs. It is possible they may function as protection against" exact="viral infection," post="but conversely, in chronic use the body may adapt"/>
 <result pre="may function as protection against viral infection, but conversely, in" exact="chronic" post="use the body may adapt to constant exposure to"/>
 <result pre="less effective. More research is needed on the effects of" exact="chronic" post="usage of lysosomotropic drugs on antiviral activity of drugs"/>
 <result pre="the LiverTox database (where A levels indicates the highest likelihood" exact="of liver" post="toxicity, and E the lowest) [36]. For cardiotoxicity, we"/>
 <result pre="were then additionally filtered according to their pKa values and" exact="primary" post="pharmacology, to find compounds less likely to induce serious"/>
 <result pre="indication than what they were developed for. This resulted in" exact="total" post="of 26 drugs with potential for repurposing for viral"/>
 <result pre="in total of 26 drugs with potential for repurposing for" exact="viral" post="infections due to the high likelihood of exhibiting antiviral"/>
 <result pre="total of 26 drugs with potential for repurposing for viral" exact="infections" post="due to the high likelihood of exhibiting antiviral effects"/>
 <result pre="are among the drugs most acceptable for repurposing since their" exact="primary" post="pharmacological activity will likely not pose a safety issue."/>
 <result pre="drugs will likely need to be avoided in patients with" exact="heart" post="conditions. Cautious approach is needed for six drugs that"/>
 <result pre="effect may still be linked to applied doses for their" exact="primary" post="indication. In addition, higher likelihood of liver toxicity was"/>
 <result pre="applied doses for their primary indication. In addition, higher likelihood" exact="of liver" post="toxicity was found in six out of 26 drugs."/>
 <result pre="countries, where it is approved for indications such as influenza," exact="acute" post="respiratory viral infection, viral hepatitis, viral encephalitis and myelitis."/>
 <result pre="where it is approved for indications such as influenza, acute" exact="respiratory" post="viral infection, viral hepatitis, viral encephalitis and myelitis. Arbidol"/>
 <result pre="it is approved for indications such as influenza, acute respiratory" exact="viral infection," post="viral hepatitis, viral encephalitis and myelitis. Arbidol is registered"/>
 <result pre="approved for indications such as influenza, acute respiratory viral infection," exact="viral hepatitis," post="viral encephalitis and myelitis. Arbidol is registered in Russia"/>
 <result pre="indications such as influenza, acute respiratory viral infection, viral hepatitis," exact="viral encephalitis" post="and myelitis. Arbidol is registered in Russia and China"/>
 <result pre="such as influenza, acute respiratory viral infection, viral hepatitis, viral" exact="encephalitis" post="and myelitis. Arbidol is registered in Russia and China"/>
 <result pre="possibly occurs via increasing the endosomal pH, and thereby preventing" exact="infection" post="of the cell. The third antiviral, nelfinavir is a"/>
 <result pre="nelfinavir is a protease inhibitor drug approved for treatment of" exact="HIV infection," post="but also reported effective against a wide variety of"/>
 <result pre="effective against a wide variety of viruses: Herpes simplex, SARS-CoV," exact="hepatitis C," post="dengue and Chikungunya [23] (DrugVirus database). It is likely"/>
 <result pre="vicriviroc, which was developed as nanomolar CCR5 antagonist for HIV" exact="infections" post="and came to phase III clinical trials where it"/>
 <result pre="to phase III clinical trials where it did not meet" exact="primary" post="efficacy endpoints. When analysing the potential of repurposing such"/>
 <result pre="in Table 2) as they failed in one of the" exact="primary" post="inclusion criteria. Three of them target respiratory system (bromhexine,"/>
 <result pre="one of the primary inclusion criteria. Three of them target" exact="respiratory" post="system (bromhexine, ambroxol and formoterol), but should be cautiously"/>
 <result pre="but should be cautiously assessed at which stages of the" exact="disease" post="they may be most effective. Interestingly, in this group"/>
 <result pre="was proven effective against SARS-CoV and MERS-CoV viruses by inhibiting" exact="viral" post="fusion and entry into the cells [39,40] and is"/>
 <result pre="[41]. Its efficacy is speculated to be linked to its" exact="primary" post="target Abl2 kinase, but it is conceivable that the"/>
 <result pre="have identified 26 drugs with high and 10 drugs with" exact="lower" post="probability of showing antiviral effects due to their lysosomotropic"/>
 <result pre="combination or alone, be capable of reducing the extent of" exact="infection" post="and helping patients avoid serious or long-term illness. Keeping"/>
 <result pre="is mounting, it is still unclear at which stage of" exact="disease" post="development endosomal pathway disruption could play the most important"/>
 <result pre="whether prior exposure to lysosomotropic drugs could help prevent the" exact="disease" post="or, on the contrary, induce adaptations in the body"/>
 <result pre="antivirals with lysosomotropic mechanism. Defining target patient populations, based on" exact="disease" post="status, drug safety profiles and other factors need to"/>
 <result pre="antivirals, suitable for repurposing to treat COVID-19 or any future" exact="viral infection" post="epidemics. Declaration of Competing Interest Authors declare no conflicts"/>
 <result pre="suitable for repurposing to treat COVID-19 or any future viral" exact="infection" post="epidemics. Declaration of Competing Interest Authors declare no conflicts"/>
 <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on viral infections:"/>
 <result pre="of emerging viral diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against todayâ€™s diseases?Lancet Infect. Dis.3200372272714592603"/>
 <result pre="Infect. Dis.3200372272714592603 4VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056916115318 5GordonD.E.JangG.M.BouhaddouM.XuJ.ObernierK.WhiteK.M.Oâ€™mearaM.J.RezeljV.V.GuoJ.Z.SwaneyD.L.TumminoT.A.HÃ¼ttenhainR.KaakeR.M.RichardsA.L.TutuncuogluB.FoussardH.BatraJ.HaasK.ModakM.KimM.HaasP.PolaccoB.J.BrabergH.FabiusJ.M.EckhardtM.SoucherayM.BennettM.J.CakirM.McgregorM.J.LiQ.MeyerB.RoeschF.ValletT.Mac KainA.MiorinL.MorenoE.NaingZ.Z.C.ZhouY.PengS.ShiY.ZhangZ.ShenW.KirbyI.T.MelnykJ.E.ChorbaJ.S.LouK.DaiS.A.Barrio-HernandezI.MemonD.Hernandez-ArmentaC.LyuJ.MathyC.J.P.PericaT.PillaK.B.GanesanS.J.SaltzbergD.J.RakeshR.LiuX.RosenthalS.B.CalvielloL.VenkataramananS.Liboy-LugoJ.LinY.HuangX.P.LiuY.WankowiczS.A.BohnM.SafariM.UgurF.S.KohC.SavarN.S.TranQ.D.ShengjulerD.FletcherS.J.Oâ€™nealM.C.CaiY.ChangJ.C.J.BroadhurstD.J.KlippstenS.SharpP.P.WenzellN.A.Kuzuoglu-OzturkD.WangH.Y.TrenkerR.YoungJ.M.CaveroD.A.HiattJ.RothT.L.RathoreU.SubramanianA.NoackJ.HubertM.StroudR.M.FrankelA.D.RosenbergO.S.VerbaK.A.AgardD.A.OttM.EmermanM.JuraN.A SARS-CoV-2 protein interaction map"/>
 <result pre="with membrane-mimetics by NMR spectroscopyJ. Med. Chem.5520125632563622612227 13GhM.S.WilhelmM.J.DaiH.L.Azithromycin-induced changes to" exact="bacterial" post="membrane properties monitoredACS Med. Chem. Lett.9201856957429937984 14FunkR.S.KriseJ.P.Cationic amphiphilic drugs"/>
 <result pre="clinical implicationsExpert Opin. Drug Metab. Toxicol.8201294395822616667 19ShaymanJ.A.AbeA.Drug induced phospholipidosis: an" exact="acquired" post="lysosomal storage disorderBiochim. Biophys. Acta1831201360261122960355 20MuniÄ‡V.BanjanacM.KoÅ¡trunS.NujiÄ‡K.BosnarM.MarjanoviÄ‡N.RaliÄ‡J.MatijaÅ¡iÄ‡M.HlevnjakM.ErakoviÄ‡ HaberV.Intensity of macrolide"/>
 <result pre="J. Infect. Dis.93202026827632081774 24BoriskinY.S.LenevaI.A.PÃ©cheurE.I.PolyakS.J.Arbidol: a broad-spectrum antiviral compound that blocks" exact="viral" post="fusionCurr. Med. Chem.152008997100518393857 25EkinsS.LingerfeltM.A.ComerJ.E.FreibergA.N.MirsalisJ.C.Oâ€™loughlinK.HarutyunyanA.McfarlaneC.GreenC.E.MadridP.B.Efficacy of tilorone dihydrochloride against ebola"/>
 <result pre="volume of distribution of compoundsChem. Res. Toxicol.23201074975520356072 36National Institute of" exact="Diabetes" post="and Digestive and Kidney Diseases (NIDDK)LiverTox Clinical and Research"/>
 <result pre="compoundsChem. Res. Toxicol.23201074975520356072 36National Institute of Diabetes and Digestive and" exact="Kidney" post="Diseases (NIDDK)LiverTox Clinical and Research Information on Drug-Induced Liver"/>
 <result pre="Res. Toxicol.23201074975520356072 36National Institute of Diabetes and Digestive and Kidney" exact="Diseases" post="(NIDDK)LiverTox Clinical and Research Information on Drug-Induced Liver Injury"/>
 <result pre="39DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.Jr.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273 40SiskJ.M.FriemanM.B.MachamerC.E.Coronavirus S protein-induced fusion"/>
 <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273 40SiskJ.M.FriemanM.B.MachamerC.E.Coronavirus S protein-induced fusion is"/>
 <result pre="hospital setting or a clinical trial due to risk of" exact="heart" post="rhythm problems [Online]. Available: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or [Accessed]. 44PubChem [Online]. Available:"/>
 <result pre="A. D. Drugs@FDA: FDA-Approved Drugs [Online] Available: https://www.accessdata.fda.gov/scripts/cder/daf/ [Accessed]. 46BjorneboeM.IversenO.OlsenS.Infective" exact="hepatitis" post="and toxic jaundice in a municipal hospital during a"/>
 <result pre="and metabolism of chloroquine. Focus on recent advancementsClin. Pharmacokinet.3119962572748896943 50HancoxJ.C.HasnainM.ViewegW.V.CrouseE.L.BaranchukA.Azithromycin," exact="cardiovascular" post="risks, QTc interval prolongation, torsade de pointes, and regulatory"/>
 <result pre="of case reportsTher. Adv. Infect. Dis.1201315516525165550 51KanekoT.DoughertyT.J.MageeT.V.Therapeutic areas II: cancer," exact="Infectious" post="diseases, inflammation &amp;amp; immunology and dermatologyComprehensiv Med. Chem. II2007"/>
 <result pre="Pharmacokinet.3019962632998983859 53Oâ€™maraE.KasserraC.HuddlestoneJ.R.WanY.SoniP.CaceresM.MedlockM.MorrisonR.DevinskyO.Effect of vicriviroc on the QT/corrected QT interval and" exact="central nervous system" post="in healthy subjectsAntimicrob. Agents Chemother.5420102448245420350942 54RidleyJ.M.MilnesJ.T.HancoxJ.C.WitchelH.J.Clemastine, a conventional antihistamine,"/>
</results>
